The Impact of Comedy vs Cancer
Setting the stage for new breakthroughs
Your support empowers MSK doctors and scientists to push boundaries and transform how the world understands, diagnoses, and treats blood cancers.
Advancing immunotherapy research
Fueled by Comedy vs Cancer, MSK researchers are pioneering advances in immunotherapy, which uses a patient’s own immune system to fight cancer cells. Today, this treatment technology is one of the most promising defenses against blood cancer.
Tackling the most common type of leukemia
Comedy vs Cancer and MSK are working hard to improve outcomes for people with acute myeloid leukemia (AML), which is caused by the uncontrolled growth of abnormal immature blood cells in the bone marrow. More than 20,000 children and adults in the United States are diagnosed with AML every year, but fewer than 30% of patients with the disease survive five years after diagnosis.
Igniting innovative research
Comedy vs Cancer plays such an important role in spurring advances in blood cancer treatment because funding is limited for most early-stage blood cancer studies. Without sufficient financial resources, researchers can spend years trying to get innovative ideas off the ground.
Impact in action
What Comedy vs Cancer funds
Bispecific antibody therapy
MSK is developing a multidisciplinary platform that can monitor the activity of bispecific antibodies in lymphoma patients in real time to better understand how this innovative immunotherapy works.
AI-Enhanced CAR T cell therapy
With the power of AI and multimodal data integration, MSK doctors are learning how to create highly personalized chimeric antigen receptor (CAR) T cell therapies in order to choose the safest and most effective option for each patient.
New clinical trial for leukemia
In a first-of-its-kind clinical trial, MSK researchers are examining if chimeric antigen receptor (CAR) T cell therapy can effectively target acute lymphoblastic leukemia without the support of chemotherapy.
